niacinamide has been researched along with Hepatitis B, Chronic in 14 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Hepatitis B, Chronic: INFLAMMATION of the LIVER in humans caused by HEPATITIS B VIRUS lasting six months or more. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hepatotoxicity induced by sorafenib and antiviral therapy is a limitation for its continuation treatment for patients with advanced hepatitis B virus-related hepatocellular carcinoma (HCC)." | 9.20 | Prospective analysis of tiopronin in prevention of sorafenib and antiviral therapy inducing liver toxicity in advanced hepatitis B virus-related hepatocellular carcinoma. ( Guo, W; Li, J; Qiu, X; Yan, B; Zhang, S, 2015) |
| "The Sorafenib Hepatocellular Carcinoma (HCC) Assessment Randomized Protocol (SHARP) trial demonstrated that sorafenib improves overall survival and is safe for patients with advanced HCC." | 9.16 | Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. ( Beaugrand, M; Bolondi, L; Bruix, J; Craxi, A; Galle, PR; Gerken, G; Llovet, JM; Marrero, JA; Mazzaferro, V; Moscovici, M; Nadel, A; Porta, C; Raoul, JL; Sangiovanni, A; Santoro, A; Shan, M; Sherman, M; Voliotis, D, 2012) |
| "Sorafenib is recommended as the treatment of choice for hepatocellular carcinoma (HCC) with extrahepatic spread (EHS)." | 7.81 | Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: treatment outcome and prognostic factors. ( Ahn, JM; Cho, JY; Choi, MS; Gwak, GY; Koh, KC; Lee, JH; Lim, HY; Paik, SW; Paik, YH; Sinn, DH; Sohn, W; Yoo, BC, 2015) |
| "Sorafenib is currently the sole molecular targeted agent that improves overall survival in advanced hepatocellular carcinoma (HCC)." | 7.81 | Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy. ( Park, JG, 2015) |
| "Sorafenib, a multitargeted tyrosine kinase inhibitor, is now the treatment of choice for systemic therapy of patients with advanced hepatocellular carcinoma (HCC)." | 7.77 | Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models. ( Baek, KK; Kang, WK; Kim, JH; Lee, J; Lim, HY; Park, JO; Park, SH; Park, YS; Uhm, JE, 2011) |
| "Hepatotoxicity induced by sorafenib and antiviral therapy is a limitation for its continuation treatment for patients with advanced hepatitis B virus-related hepatocellular carcinoma (HCC)." | 5.20 | Prospective analysis of tiopronin in prevention of sorafenib and antiviral therapy inducing liver toxicity in advanced hepatitis B virus-related hepatocellular carcinoma. ( Guo, W; Li, J; Qiu, X; Yan, B; Zhang, S, 2015) |
| "The Sorafenib Hepatocellular Carcinoma (HCC) Assessment Randomized Protocol (SHARP) trial demonstrated that sorafenib improves overall survival and is safe for patients with advanced HCC." | 5.16 | Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. ( Beaugrand, M; Bolondi, L; Bruix, J; Craxi, A; Galle, PR; Gerken, G; Llovet, JM; Marrero, JA; Mazzaferro, V; Moscovici, M; Nadel, A; Porta, C; Raoul, JL; Sangiovanni, A; Santoro, A; Shan, M; Sherman, M; Voliotis, D, 2012) |
| "Sorafenib is recommended as the treatment of choice for hepatocellular carcinoma (HCC) with extrahepatic spread (EHS)." | 3.81 | Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: treatment outcome and prognostic factors. ( Ahn, JM; Cho, JY; Choi, MS; Gwak, GY; Koh, KC; Lee, JH; Lim, HY; Paik, SW; Paik, YH; Sinn, DH; Sohn, W; Yoo, BC, 2015) |
| "Sorafenib is currently the sole molecular targeted agent that improves overall survival in advanced hepatocellular carcinoma (HCC)." | 3.81 | Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy. ( Park, JG, 2015) |
| "Sorafenib, a multitargeted tyrosine kinase inhibitor, is now the treatment of choice for systemic therapy of patients with advanced hepatocellular carcinoma (HCC)." | 3.77 | Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models. ( Baek, KK; Kang, WK; Kim, JH; Lee, J; Lim, HY; Park, JO; Park, SH; Park, YS; Uhm, JE, 2011) |
| "Hepatocellular carcinoma is the leading cause of death in cirrhosis." | 2.46 | Review article: the management of hepatocellular carcinoma. ( Cabrera, R; Nelson, DR, 2010) |
| "The occurrence of hepatocellular carcinoma is about 3-15 % in patients with alcoholic liver disease." | 2.46 | [Hepatocellular carcinoma: occurrence, risk factors, biomarkers]. ( Fehér, J; Lengyel, G, 2010) |
| "Mean survival in hepatocellular carcinoma remains low." | 1.42 | Multidisciplinary Approach in Hepatocellular Carcinoma in a Level II Hospital: The First Decade of Hospital Universitario Fundacion Alcorcon. ( Alonso López, S; Burgos, Rde L; Fernandez Cebrián, JM; Fernández Rodríguez, C; Gutiérrez Garcia, ML; LIedó Navarro, JL; Loinaz Segurola, C; Martel Villagrán, J; Martín Ríos, D; Ochando Cerdán, F, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 13 (92.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sohn, W | 1 |
| Paik, YH | 1 |
| Cho, JY | 1 |
| Lim, HY | 2 |
| Ahn, JM | 1 |
| Sinn, DH | 1 |
| Gwak, GY | 1 |
| Choi, MS | 1 |
| Lee, JH | 1 |
| Koh, KC | 1 |
| Paik, SW | 1 |
| Yoo, BC | 1 |
| Yang, Y | 1 |
| Wen, F | 1 |
| Li, J | 2 |
| Zhang, P | 1 |
| Yan, W | 1 |
| Hao, P | 1 |
| Xia, F | 1 |
| Bi, F | 1 |
| Li, Q | 1 |
| Qiu, X | 1 |
| Guo, W | 1 |
| Yan, B | 1 |
| Zhang, S | 1 |
| Park, JG | 1 |
| Loinaz Segurola, C | 1 |
| LIedó Navarro, JL | 1 |
| Burgos, Rde L | 1 |
| Martín Ríos, D | 1 |
| Ochando Cerdán, F | 1 |
| Alonso López, S | 1 |
| Martel Villagrán, J | 1 |
| Gutiérrez Garcia, ML | 1 |
| Fernandez Cebrián, JM | 1 |
| Fernández Rodríguez, C | 1 |
| Dika, IE | 1 |
| Harding, JJ | 1 |
| Abou-Alfa, GK | 1 |
| Cabrera, R | 1 |
| Nelson, DR | 1 |
| Yeganeh, M | 1 |
| Finn, RS | 1 |
| Saab, S | 1 |
| Fehér, J | 1 |
| Lengyel, G | 1 |
| Iavarone, M | 1 |
| Perrino, M | 1 |
| Viganò, M | 1 |
| Beck-Peccoz, P | 1 |
| Fugazzola, L | 1 |
| Villanueva, A | 1 |
| Newell, P | 1 |
| Hoshida, Y | 1 |
| Baek, KK | 1 |
| Kim, JH | 1 |
| Uhm, JE | 1 |
| Park, SH | 1 |
| Lee, J | 1 |
| Park, JO | 1 |
| Park, YS | 1 |
| Kang, WK | 1 |
| Nguyen, V | 1 |
| George, J | 1 |
| van der Poorten, D | 1 |
| Bruix, J | 1 |
| Raoul, JL | 1 |
| Sherman, M | 1 |
| Mazzaferro, V | 1 |
| Bolondi, L | 1 |
| Craxi, A | 1 |
| Galle, PR | 1 |
| Santoro, A | 1 |
| Beaugrand, M | 1 |
| Sangiovanni, A | 1 |
| Porta, C | 1 |
| Gerken, G | 1 |
| Marrero, JA | 1 |
| Nadel, A | 1 |
| Shan, M | 1 |
| Moscovici, M | 1 |
| Voliotis, D | 1 |
| Llovet, JM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective Cohort Study of Single Agent Memantine in Patients With Child-Pugh Score ≥ B7 Cirrhosis and Hepatocellular Carcinoma[NCT06007846] | Phase 2/Phase 3 | 12 participants (Anticipated) | Interventional | 2023-07-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for niacinamide and Hepatitis B, Chronic
| Article | Year |
|---|---|
Hepatocellular carcinoma in patients with HIV.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Coinfection; Hepatitis B, Chronic; Hepatitis C, Ch | 2017 |
Review article: the management of hepatocellular carcinoma.
Topics: Ablation Techniques; Adult; Antineoplastic Agents; Asian People; Benzenesulfonates; Biopsy; Black Pe | 2010 |
[Hepatocellular carcinoma: occurrence, risk factors, biomarkers].
Topics: Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; Copper; Deve | 2010 |
Inherited hepatocellular carcinoma.
Topics: Algorithms; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; | 2010 |
2 trials available for niacinamide and Hepatitis B, Chronic
| Article | Year |
|---|---|
Prospective analysis of tiopronin in prevention of sorafenib and antiviral therapy inducing liver toxicity in advanced hepatitis B virus-related hepatocellular carcinoma.
Topics: Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Femal | 2015 |
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.
Topics: Aged; Alcoholism; Antineoplastic Agents; Carcinoma, Hepatocellular; Diarrhea; Disease Progression; F | 2012 |
8 other studies available for niacinamide and Hepatitis B, Chronic
| Article | Year |
|---|---|
Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: treatment outcome and prognostic factors.
Topics: Aged; Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Femal | 2015 |
A high baseline HBV load and antiviral therapy affect the survival of patients with advanced HBV-related HCC treated with sorafenib.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Female; Hepatectomy; Hepatitis | 2015 |
Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy.
Topics: Adult; Aged; alpha-Fetoproteins; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular | 2015 |
Multidisciplinary Approach in Hepatocellular Carcinoma in a Level II Hospital: The First Decade of Hospital Universitario Fundacion Alcorcon.
Topics: Ablation Techniques; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chem | 2015 |
Apparent remission of a solitary metastatic pulmonary lesion in a liver transplant recipient treated with sorafenib.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Combined Modality Therapy; Hep | 2009 |
Sorafenib-induced destructive thyroiditis.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chronic Disease; Hepatitis B, C | 2010 |
Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2011 |
A maxillary mass in a HBV-cirrhotic patient.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Biopsy; Carcinoma, Hepatocellular | 2012 |